AEterna Zentaris (AEZS) Partner, Keryx Biopharmaceuticals (KERX), Announces Poster Presentation Highlighting Clinical Activity of Perifosine (KRX-0401) at 51st Annual Meeting of the American Society of Hematology
11/11/2009 7:50:24 AM
More...
|
AEterna Zentaris (AEZS) Narrows Q3 Loss
11/11/2009 6:23:27 AM
More...
|
AEterna Zentaris (AEZS) Scientific Article Supports Perifosine's Development in Kidney Cancer
11/9/2009 11:13:31 AM
More...
|
AEterna Zentaris (AEZS) to Announce Third Quarter 2009 Financial and Operating Results on November 11, 2009
11/4/2009 8:13:11 AM
More...
|
AEterna Zentaris (AEZS) Announces Positive Preliminary Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Ovarian Cancer
11/2/2009 8:17:18 AM
More...
|
AEterna Zentaris (AEZS) Receives $5.5 Million from Institutional Investors
10/26/2009 7:11:55 AM
More...
|
AEterna Zentaris (AEZS) to Raise $5.5 Million from Institutional Investors at $1.20 Per Share
10/20/2009 7:34:49 AM
More...
|
AEterna Zentaris (AEZS) to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test for Growth Hormone Deficiency
10/19/2009 8:50:47 AM
More...
|
AEterna Zentaris (AEZS) to Present at BioContact in Quebec City on October 8
10/1/2009 10:21:52 AM
More...
|
AEterna Zentaris (AEZS): Thorough QT Trial with Cetrorelix in Benign Prostatic Hyperplasia Meets Primary Endpoint
9/30/2009 6:58:52 AM
More...
|
|